Mass Drug Administration of Dihydroartemisinin-piperaquine + Single Low-dose Primaquine to Accelerate Toward Elimination Activities

NACompletedINTERVENTIONAL
Enrollment

10,715

Participants

Timeline

Start Date

June 19, 2021

Primary Completion Date

December 31, 2022

Study Completion Date

June 30, 2023

Conditions
Malaria,FalciparumMalaria
Interventions
DRUG

Dihydroartemisinin-piperaquine

DHA-PPQ will be given over the course of three consecutive days using 160mg/20mg or 320mg/40mg of dihydroartemisinin/piperaquine tablets. DHA-PPQ will be administered via age-based dosing. All three doses will be directly observed and given orally with water and without food.

DRUG

Primaquine

Primaquine will be given once with the first dose of DHA-PPQ. Primaquine will be administered in an aqueous solution according to age-based dosing guidelines.

Trial Locations (1)

Unknown

Tambacounda Health District, Tambacounda

Sponsors
All Listed Sponsors
collaborator

L'université de Thiès

OTHER

collaborator

Programme National de Lutte contre le Paludisme (PNLP), Senegal

UNKNOWN

collaborator

Population Services International

OTHER

collaborator

Centers for Disease Control and Prevention

FED

collaborator

US President's Malaria Initiative

UNKNOWN

lead

University of California, San Francisco

OTHER

NCT04864444 - Mass Drug Administration of Dihydroartemisinin-piperaquine + Single Low-dose Primaquine to Accelerate Toward Elimination Activities | Biotech Hunter | Biotech Hunter